Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Gabexate Mesylate In The Prevention Of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review And Meta-analysis Update.

Minghua Zheng, J. Bai, Maobin Meng, Y. Chen
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP), and the benefit of pharmacologic treatment of the condition is unclear. Although prophylactic use of gabexate mesylate (GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncertainty remains regarding the effectiveness of GM treatment in post-ERCP pancreatitis (PEP). OBJECTIVE The aim of this study was to determine through systematic review and meta-analysis the effectiveness and tolerability of GM in the prophylaxis of PEP. METHODS MEDLINE (January 1966-July 2007), EMBASE (January 1966- July 2007), the Cochrane Controlled Trials Register on The Cochrane Library (Issue 2, 2007), and the China Biological Medicine Database (January 1978-July 2007) were searched. We used the method recommended by The Cochrane Collaboration to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) of GM in the prevention of PEP. RESULTS Of the 38 studies identified, 31 were excluded for the following reasons: they were reviews or editorials (9 articles); were meta-analyses (4); had differences in cointerventions (4); were nonrandomized controlled trials or had incorrect randomization (4); were repeat publications (2); lacked a placebo group (1); or other (7). Seven RCTs, totaling 2883 patients, conducted in a variety of languages were included in the meta-analysis. When the RCTs were analyzed, odds ratios for GM were 0.65 (95% CI, 0.36-1.18; P 0.16) for PER 1.90 (95% CI, 0.54-6.65; P 0.32) for severe PEP, 0.55 (95% CI, 0.17-1.77; P 0.32) for the case-fatality ratio of PEP, 0.88 (95% CI, 0.74-1.05; P 0.16) for post-ERCP hyperamylasemia, and 0.78 (95% CI, 0.49 1.25; P 0.30) for post-ERCP abdominal pain. No evidence of publication bias was found. CONCLUSIONS No beneficial effects of GM on acute pancreatitis, the PEP mortality rate, or post-ERCP abdominal pain or hyperamylasemia were found; therefore, GM cannot be recommended for the prophylaxis of PEP.
This paper references
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
10.1016/S0140-6736(99)04149-5
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
D. Moher (1999)
10.1053/J.GASTRO.2003.12.035
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Olusola Oiofinlade (2004)
10.1016/J.GIE.2006.10.030
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
A. Andriulli (2007)
10.1016/S0016-5107(02)70178-8
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
F. Prat (2002)
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
10.1002/9781119536604
Cochrane Handbook for Systematic Reviews of Interventions
Michele Tarsilla (2010)
Gabexate mesylate in the prevention of post - endoscopic retrograde cholangiopancreatography pancreatitis : a systematic review and meta - analysis update
M Zheng
A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
J. Sternlieb (1992)
Effect of a new enzyme inhibitor ( gabexate mesilate - FOY ) on hyperenzymemia induced by ERCP : A double blind study
G Cavallini (1985)
10.1111/j.1572-0241.2003.07698.x
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis
E. Masci (2003)
10.1136/gut.33.8.1129
Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?
K. Binmoeller (1992)
10.1016/S0140-6736(98)01085-X
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
D. Moher (1998)
10.1016/J.GIE.2007.02.055
Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
G. Manes (2007)
Meta - analysis of prophylactic allopurinol use in post - ERCP pancreatitis
M Zheng
Gabexate in the prophylaxis ofpost - ERCP pancreatitis : A meta - analysis of randomized controlled trials
X Yang (2007)
10.1016/S0016-5107(91)70620-2
The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography.
Z. Tulassay (1991)
10.1016/S1542-3565(04)00295-2
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
A. Andriulli (2004)
10.2307/2533446
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
10.1136/bmj.315.7109.629
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
10.1186/1471-230X-8-6
Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis
M. Zheng (2008)
Prophylactic effects of preoperative administration of gabexate mesilate (FOY) on post-ERCP pancreatitis
Y Shimizu (1979)
10.1097/00006676-199105000-00013
ERCP‐ and Endoscopic Sphincterotomy‐Induced Pancreatitis
S. Sherman (1991)
The role ofglucagon in endoscopic cholangiopancreatography
SE Silvis (1975)
10.1016/S0016-5107(77)73457-1
Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol.
R. Brust (1977)
10.1159/000051450
Pathophysiology of Pancreatitis
A. Saluja (1999)
10.1097/00006676-199205000-00023
ERCP and endoscopic sphincterotomy-induced pancreatitis.
S. Sherman (1994)
Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
A. Andriulli (2003)
Prophylactic effect of Gabexate on post-ERCP pancreatitis: a clinical observation.
X. Guang (2005)
Gabexte in Digestive Endoscopy-Italian Group II. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis
E Masci (2003)
10.1159/000198070
Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography.
H. Odes (1977)
10.1016/S0016-5107(02)70431-8
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
A. Andriulli (2002)
Effect of a new enzyme inhibitor (gabexate mesilateFOY) on hyperenzymemia induced by ERCP: A double blind study. Digestion
L Benini (1985)
10.1136/bmj.323.7310.446
Concealing treatment allocation in randomised trials
D. Altman (2001)
10.1590/S0100-879X2006000100010
Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
G-S Xiong (2006)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
10.1056/NEJM199609263351302
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
10.1186/1471-230X-7-6
Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials
M. Zheng (2007)
10.1016/S0016-5107(95)90002-0
The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy.
R. Arcidiacono (1994)
10.7326/0003-4819-123-11-199512010-00010
Discordance between Meta-analyses and Large-Scale Randomized, Controlled Trials: Examples from the Management of Acute Myocardial Infarction
S. Borzak (1995)
10.1016/S1590-8658(06)80037-X
Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesylate: A randomized placebo controlled multicenter study
S. Benvenuti (2006)
The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. G~strointest Endosc
Z Tulassay (1991)
10.1056/NEJM199609263351302
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
10.1016/0197-2456(95)00134-4
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A. Jadad (1996)
10.1016/S0016-5107(75)73837-3
The role of glucagon in endoscopic cholangiopancreatography.
S. Silvis (1975)
10.1016/J.GIE.2006.03.831
Prevention of Post-ERCP Pancreatitis with Somatostatin Versus Gabexate Mesilate: A Randomized Placebo Controlled Multicenter Study
S. Benvenuti (2006)
; 7 : 402 ]
PB Cotton (1991)
Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography
K Hajiro (1978)
10.1016/S0016-5085(89)80087-3
Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis.
G. Ohshio (1989)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar